BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28432657)

  • 21. Copper-topotecan complexation mediates drug accumulation into liposomes.
    Taggar AS; Alnajim J; Anantha M; Thomas A; Webb M; Ramsay E; Bally MB
    J Control Release; 2006 Aug; 114(1):78-88. PubMed ID: 16842880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery.
    Haghiralsadat F; Amoabediny G; Helder MN; Naderinezhad S; Sheikhha MH; Forouzanfar T; Zandieh-Doulabi B
    Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):169-177. PubMed ID: 28376641
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accelerated blood clearance of pegylated liposomal topotecan: influence of polyethylene glycol grafting density and animal species.
    Li C; Cao J; Wang Y; Zhao X; Deng C; Wei N; Yang J; Cui J
    J Pharm Sci; 2012 Oct; 101(10):3864-76. PubMed ID: 22777607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thermosensitive, near-infrared-labeled nanoparticles for topotecan delivery to tumors.
    Rosca EV; Wright M; Gonitel R; Gedroyc W; Miller AD; Thanou M
    Mol Pharm; 2015 May; 12(5):1335-46. PubMed ID: 25826624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations.
    Johnston MJ; Semple SC; Klimuk SK; Edwards K; Eisenhardt ML; Leng EC; Karlsson G; Yanko D; Cullis PR
    Biochim Biophys Acta; 2006 Jan; 1758(1):55-64. PubMed ID: 16487476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An in vitro assessment of liposomal topotecan simulating metronomic chemotherapy in combination with radiation in tumor-endothelial spheroids.
    Jyoti A; Fugit KD; Sethi P; McGarry RC; Anderson BD; Upreti M
    Sci Rep; 2015 Oct; 5():15236. PubMed ID: 26468877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.
    Hao YL; Deng YJ; Chen Y; Wang KZ; Hao AJ; Zhang Y
    J Pharm Pharmacol; 2005 Oct; 57(10):1279-87. PubMed ID: 16259756
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel stealth liposomal topotecan with amlodipine: apoptotic effect is associated with deletion of intracellular Ca2+ by amlodipine thus leading to an enhanced antitumor activity in leukemia.
    Li X; Ruan GR; Lu WL; Hong HY; Liang GW; Zhang YT; Liu Y; Long C; Ma X; Yuan L; Wang JC; Zhang X; Zhang Q
    J Control Release; 2006 May; 112(2):186-98. PubMed ID: 16516327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. pH-responsive and folate-coated liposomes encapsulating irinotecan as an alternative to improve efficacy of colorectal cancer treatment.
    Nunes SS; Miranda SEM; de Oliveira Silva J; Fernandes RS; de Alcântara Lemos J; de Aguiar Ferreira C; Townsend DM; Cassali GD; Oliveira MC; Branco de Barros AL
    Biomed Pharmacother; 2021 Dec; 144():112317. PubMed ID: 34634556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models.
    Tardi P; Choice E; Masin D; Redelmeier T; Bally M; Madden TD
    Cancer Res; 2000 Jul; 60(13):3389-93. PubMed ID: 10910044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of the physicochemical state of interior agents to prepare controlled release liposomes.
    Wang N; Wang T; Li T; Deng Y
    Colloids Surf B Biointerfaces; 2009 Mar; 69(2):232-8. PubMed ID: 19131224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy.
    Zucker D; Andriyanov AV; Steiner A; Raviv U; Barenholz Y
    J Control Release; 2012 Jun; 160(2):281-9. PubMed ID: 22019556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of stealthy liposomal topotecan plus amlodipine on the multidrug-resistant leukaemia cells in vitro and xenograft in mice.
    Li X; Lu WL; Liang GW; Ruan GR; Hong HY; Long C; Zhang YT; Liu Y; Wang JC; Zhang X; Zhang Q
    Eur J Clin Invest; 2006 Jun; 36(6):409-18. PubMed ID: 16684125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within liposomes.
    Abraham SA; Edwards K; Karlsson G; Hudon N; Mayer LD; Bally MB
    J Control Release; 2004 May; 96(3):449-61. PubMed ID: 15120901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure.
    Danks MK; Pawlik CA; Whipple DO; Wolverton JS
    Clin Cancer Res; 1997 Oct; 3(10):1731-8. PubMed ID: 9815557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolongation of time interval between doses could eliminate accelerated blood clearance phenomenon induced by pegylated liposomal topotecan.
    Li C; Zhao X; Wang Y; Yang H; Li H; Li H; Tian W; Yang J; Cui J
    Int J Pharm; 2013 Feb; 443(1-2):17-25. PubMed ID: 23318366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation.
    Li C; Cui J; Wang C; Li Y; Zhang L; Xiu X; Li Y; Wei N; Zhang L; Wang P
    J Pharm Pharmacol; 2011 Jun; 63(6):765-73. PubMed ID: 21585373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals.
    Du J; Lu WL; Ying X; Liu Y; Du P; Tian W; Men Y; Guo J; Zhang Y; Li RJ; Zhou J; Lou JN; Wang JC; Zhang X; Zhang Q
    Mol Pharm; 2009; 6(3):905-17. PubMed ID: 19344115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan.
    Subramanian D; Muller MT
    Oncol Res; 1995; 7(9):461-9. PubMed ID: 8835290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The combination of A-966492 and Topotecan for effective radiosensitization on glioblastoma spheroids.
    Koosha F; Neshasteh-Riz A; Takavar A; Eyvazzadeh N; Mazaheri Z; Eynali S; Mousavi M
    Biochem Biophys Res Commun; 2017 Sep; 491(4):1092-1097. PubMed ID: 28797568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.